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the infrarenal aorta, and aortic aneurysm, but late aneurys-
mal dilatation and subsequent rupture were the major rea-
sons for the abandonment of this technique.2,3 The
successful resurgence of refrigerated allograft replacement
in the management of arterial infections was reported by
Kieffer.4 Since then, promising clinical results have been
achieved with the use of cryopreserved arterial allografts
implanted in infected sites.5,6 A considerable incidence of
late allograft-related complications7 and reports of early
ruptures and cracks in cryopreserved arterial allografts8
prompted us to review our results with the use of cryo-
preserved arterial allografts in the treatment of major vas-
cular infection and to analyze safeguards and technical
pitfalls with the use of allografts that influence early and
midterm mortality.
PATIENTS AND METHODS
Patient characteristics. Between 1990 and 1999,
cryopreserved arterial allografts were implanted in 49
patients, 21 (43%) with a mycotic aneurysm and 28 (57%)
with a prosthetic graft infection of the thoracic (n = 16;
33%) or abdominal aorta (n = 33; 67%). The ascending
aorta was affected in five patients (10%), the transverse
arch and descending aorta in 11 patients (23%), and the
infrarenal abdominal aorta including pelvic (14 patients;
28%) and groin (19 patients; 39%) vessels in the remaining
33 patients (67%). The types of bacterial organisms cul-
tured in these patients are summarized in Table 1.
Infections of the vascular system and infections of
arterial grafts are a special challenge to the vascular sur-
geon. The standard approach to infection emphasizes
wide debridment of infected tissue, excision of the
infected prosthesis, and arterial reconstruction with auto-
logous or remotely placed prosthetic bypass grafts. Results
with conventional management of aortic infection have
improved for the treatment of mycotic aneurysm of the
infrarenal aorta.1 However, the ultimate outcome for
complicated aortic infection and particularly prosthetic
aortic graft infection remains unpredictable and is associ-
ated with a disappointingly high mortality and complica-
tion rate.
The aortic allograft was the first vascular device used
as a means of treating aortic coarctation, obstruction of
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Purpose: In situ repair with cryopreserved vascular allografts improves the results in the surgical treatment of aortic infec-
tion. This study evaluated the technical pitfalls with the use of allografts that influence early and midterm mortality. 
Methods: Between 1990 and 1999, 49 patients, 21 (43%) with a mycotic aneurysm and 28 (57%) with a prosthetic graft
infection of the thoracic and abdominal aorta including pelvic and groin vessels, underwent in situ repair with cryo-
preserved arterial allografts. Seventeen patients (35%) had aortobronchial, aortoesophageal, or aortoenteric fistulas.
Results: Allograft-related technical problems occurred in eight patients (16%) in this series, and they included: intraop-
erative rupture caused by allograft friability; allograftenteric fistula from ligated allograft side branches rupturing 8,
18, and 48 months after implantation; anastomotic failure caused by inappropriate mechanical stress; anastomotic stric-
ture after partial replacement of infected prosthetic grafts; allograft failure caused by inappropriate wound drainage;
and recurrence of infection after inappropriate duration of antifungal treatment. Seven of the eight technical problems
(87%) occurred in the first 10 patients (80%) in this series. There was one technical failure in the remaining 39 patients
(2.6%; P = .0002) because of various technical adaptations, such as critical selection of allografts, use of allograft strips
supporting large anastomoses, sealing with antibiotic-impregnated fibrin glue, and change in technique of allograft
side-branch ligature. The 30-day mortality rate was 6% for the whole series; however, it was 2.6% for last 39 patients,
with no recurrence of infection or allograft-related late death.
Conclusions: In situ repair with cryopreserved arterial allografts achieves excellent early and late results in the treatment
of aortic infection. However, distinct allograft-related technical problems had to be overcome to improve the outcome
of patients with major vascular infections. (J Vasc Surg 2002;35:80-6.)
Staphylococcus aureus and Staphylococcus coagulase nega-
tive were the most frequently found infectious agents.
Fungal infections were diagnosed in eight patients (16%).
Methods used to diagnose vascular infection included
magnetic resonance imaging and computed tomography
scanning in all patients. Conventional angiography was
not routinely used, and radionuclide scintigraphy was per-
formed in one patient only. In addition, transesophageal
echocardiography was performed in all patients with a
thoracic aortic infection.
The selection of this surgical technique was dependent
on the presence of a cryopreserved allograft; therefore, it
was not a consecutive series of patients because there were
another 41 patients during this period of observation who
were undergoing prosthetic in situ repair or extra-
anatomic bypass grafting for major vascular infection.
Comparison between the use of allografts and conven-
tional surgical techniques in a smaller series of patients has
been published.9
The mean age of these 49 patients with an allograft was
61 ± 14 years (median age, 62 years; range, 28-85 years).
Emergency surgical procedures were performed in 30
patients (61%), preoperative blood culture results were pos-
itive in 31 patients (63%), and antibiotic treatment, lasting
for 4 ± 7 months (range, 1-36 months), had been started in
38 patients (78%). A mean of 3 ± 1 surgical procedures
(median, 1 procedure; range, 1-10 procedures) had been
performed per patient before insertion of a cryopreserved
arterial allograft. The time from the first vascular procedure
to the diagnosis of infection showed a wide variation,
between 1 day and 25 years. Aortobronchial, aorto
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esophageal, and aortoenteric fistulas were found in 17
patients (35%).
Allograft selection. Preparation and cryopreserva-
tion of allografts and the surgical techniques have been
described elsewhere in detail.10,11 Large arteries were pro-
cured from brain-dead multiorgan donors or non-heart-
beating donors, aged 15 to 45 years. Arteries removed at
our institution were sent to the European Homograft
Bank in Brussels. Because of the widespread organ donor
shortage, allografts were obtained from the entire
European network of allograft banks, supported by a
bioimplant service company (BIS Foundation) connected
to the Eurotransplant Foundation in Leiden, The
Netherlands, which facilitated the urgent search and dis-
tribution of adequately sized allografts within several
Western European countries. Although minor details may
vary between various allograft banks, selection, antibiotic
decontamination, and cryopreservation of arterial allo-
grafts is widely standardized.12 After cryopreservation in
liquid nitrogen to –100°C, allografts were stored in the
vapor phase of liquid nitrogen at –180°C, and delivered in
a cryogenic dry shipper, which maintained a temperature
of –130°C. Allografts were thawed and washed immedi-
ately before implantation. Refrigerated or freshly im-
planted arterial allografts were not used in this series.
Operative technique. Basic surgical principles com-
prised one stage of in situ repair of mycotic aneurysm and
infected prosthetic grafts with cryopreserved arterial allo-
grafts. After excision of infected vascular segments and
minimal perivascular debridment, allografts were inserted
end-to-end to the normal aorta by using a single non-
absorbable running polypropylene suture. To replace the
ascending aorta and transverse arch, median sternotomy
and cold retrograde blood cardioplegia were used and
completed with hypothermic circulatory arrest and retro-
grade cerebral perfusion, as necessary. The descending
aorta was approached through a left posterior thoraco-
tomy by using partial venoarterial bypass grafting at mod-
Fig 1. Magnetic resonance angiography in a 64-year old female
patient with mycotic aneurysm of the descending thoracic aorta
showing erosion of vertebral bodies caused by the infectious dis-
ease process.
Fig 2. Intraoperative view of Fig 1 showing a mycotic aneurysm
of the supradiaphragmatic segment of the descending thoracic
aorta, caused by Streptococcus pneumonia.
erate hypothermia instituted via the left groin vessels. A
standard midline incision or a left or right retroperitoneal
approach was used for infrarenal abdominal aortic infec-
tion, as convenient. Usually, total excision of infected
prosthetic grafts was advised; however, when the vascular
prosthetic infection was limited, involving only a small
portion of the graft or the anastomosis itself, partial graft
replacement with allografts was performed at the site of
infection only. In these patients, allografts were anasto-
mosed end-to-end to the remaining prosthetic vascular
graft, covering the entire visible part of the vascular pros-
thesis with gentamycin-impregnated fibrin glue that was
manufactured at the table. Specific cultures of the fabric at
the line of resection were not performed, and the precise
location of these anastomosis was decided macroscopically
and according to the presence of adequate or inadequate
incorporation of the graft into the body’s tissue. The
ascending aorta was replaced in five patients (10%), and
the descending thoracic aorta was replaced in 11 patients
(22%). Abdominal aortic surgery was performed in 33
patients (68%), with aortoiliac reconstruction in 20
patients (41%) and aortofemoral procedures in 13 patients
(27%). In seven patients (15%), in situ repair with allo-
grafts and simultaneous surgery for intra-abdominal infec-
tions had to be carried out. There were several associated
procedures performed in these patients, which empha-
sized the co-morbidity of the patients and the complexity
of the surgical procedures (Table II).
Microbiology and antibiotic treatment. Intra-
operative tissue specimen or aspirates underwent rapid
Gram staining and examinations for aerobes and anaerobes
with appropriate culture media. The routine duration of
postoperative antibiotic treatment was 6 weeks, which was
decided on the basis of the experience and recommenda-
tions made with the perioperative and postoperative antibi-
otic treatment in patients undergoing surgery for acute
aortic valve endocarditis. However, postoperative antibi-
otic treatment was individualized for each patient, depend-
ing on the perioperative microbiological findings, the
antimicrobial susceptibility testing, the type of the infec-
tious agent, the severity and extension of the infection as
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determined intraoperatively, and the postoperative course.
Thus, the mean duration of postoperative antibiotic treat-
ment was 42 ± 19 days (median, 42 days; range, 21-90
days), with each patient’s case being discussed with the
infectious disease consultant. In one patient with a mycotic
aneurysm of the descending thoracic aorta caused by
Streptococcus pneumonia, antibiotic treatment was ex-
tended for as long as 6 months because of infection-related
deep erosion of two vertebral bodies (Figs 1 and 2).
Follow-up and statistical analysis. Follow-up infor-
mation was obtained by means of routine performance of
postoperative computed tomography scanning, magnetic
resonance imaging-angiography, transesophageal echocar-
diography, or intravenous digital subtraction angiography.
In addition, referring hospitals, the primary care physician,
and, in the case of late death, pathologists were directly
contacted. The mean follow-up period was 27 ± 21
months (median, 21 months; range, 2 to 8.6 years).
Data are presented as the mean, median, and frequen-
cies. Categorical data were assessed by using the Fisher
exact test to compare effectiveness of technical modifica-
tions and postoperative complications. Disease-related
survival and survival free of reoperation rates were calcu-
lated by means of Kaplan-Meier analysis. Calculations
were performed with the statistical package SPSS for
Windows version 9.0 (SPSS, Chicago, Ill).
RESULTS
Early mortality and reoperation. The 30-day mortal-
ity rate was 6% (3/49), with one allograft-related early
death. A 65-year-old patient with a prosthetic abdominal
aortic graft infection and an aortoenteric fistula died of allo-
graft rupture on the seventh postoperative day, presumably
caused by recurrent aortoenteric fistula because of persis-
tence of infection in the abdominal cavity. Thus, the 30-day
mortality rate for patients with aortoenteric fistula was 14%.
There were two allograft-related early reoperations,
one for allograft-thrombosis associated with peripheral
arterial occlusive disease and another for postoperative
bleeding of an infrarenal tube allograft.
Late mortality and reoperation. The allograft-related
late mortality rate was 6.5%; three patients died of allograft-
Table I. Types of bacterial organisms in patients (n =
49) undergoing cryopreserved arterial allograft replace-
ment for aortic infection
Staphylococcus aureus
Staphylococcus coagulase negative
Streptococcus pneumoniae
Pseudomonas aeruginosa
Enterococci
Escherichia coli
Candida albicans
Candida parapsilosis
Aspergillus fumigatus
Mycobacterium tuberculosis
Propionibacterium acnes
Salmonella typhii
Table II. Major concomitant procedures (n = 13) in
patients (n = 49) undergoing cryopreserved arterial allo-
graft replacement for aortic infection
Coronary artery bypass grafting for left main stenosis
Renal artery bypass grafting
Debridment of vertebral bodies
Thrombendarterectomy pelvic and groin vessels
Root replacement with valved allograft for infectious endocarditis
Resection of the left colon
Resection of the right colon
Resection of three segments of small intestine
Hartmann’s operation for perforated diverticulitis
Renal transplant nephrectomy
Controlled reperfusion of acutely ischemic limb
enteric fistulas 8, 18, and 48 months postoperatively. Of
these, two patients, an 85-year-old woman and an 82-year-
old man, were considered unfit for surgery at the time of
hospital referral for the aortoenteric fistula. The third
patient, a 44-year-old woman, died of perioperative sepsis
and multiple organ failure after emergency allograft repair.
The late mortality rate, unrelated to aortic infection or
insertion of allografts, was 20%, again taking into account
the considerable multiple organ morbidity in this particu-
lar patient population. These late deaths were caused by
heart failure in three patients, end-stage nephropathy in
two patients, liver cirrhosis in two patients, and postoper-
ative multiple organ failure after an unrelated operation in
a 78-year-old man 2 years after allograft insertion com-
bined with Hartmann’s operation for perforated divertic-
ulitis. The last patient died of intra-abdominal bleeding 9
months after partial right iliacofemoral retroperitoneal
allograft replacement for a localized infection of the right
leg of an earlier implanted bifurcation prosthesis. At
autopsy, the right iliacofemoral allograft and the anasto-
mosis to the right leg of the bifurcation prosthesis, done
by using a complete retroperitoneal approach, were incon-
spicuous. Although intra-abdominal infection of the
remaining infrarenal graft could not be verified, the cause
of this late death could not be convincingly demonstrated,
despite direct contact with the pathologist, and the persis-
tence of a low-grade infection of the remaining intra-
abdominal bifurcation prosthesis cannot be ruled out
completely.
There were three late allograft-related reinterventions,
one for a degenerated 8-year-old ascending aortic allo-
graft, one for late allograft-enteric fistula, as previously
mentioned, and one for acquired, symptomatic thoracic
aortic coarctation caused by progressive stenosis of an allo-
graft-to-descending prosthetic graft anastomosis 18
months after partial allograft replacement for prosthetic
aortoesophageal fistula, relieved by means of percutaneous
vascular stent placement.13
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Perioperative complications, hospital discharge,
and late survival. The overall perioperative complication
rate was 20%, and complications included sepsis in eight
patients (17%), pneumonia in eight patients (16%), acute
renal failure necessitating arteriovenous hemofiltration in
two patients (4%), and surgical wound revision in five
patients (10%). Nevertheless, primary uneventful wound
healing was observed in 36 patients (73%), and 46 of 49
patients (94%) were discharged from the hospital. The
mean duration of postoperative mechanical ventilation was
3 ± 5 days (median, 1 day; range, 1-28 days), the mean
length of stay in the intensive care unit was 5 ± 9 days
(median, 2 days; range, 1-42 days), and the mean in-
hospital length of stay was 36 ± 21 days (median, 28 days;
range, 8-90 days). The overall actuarial survival rate was
40% ± 14%, and overall survival free of reoperation rate
was 40% ± 13%. However, the disease-related actuarial sur-
vival rate was 76% ± 11%, and the disease-related survival
free of reoperation rate was 73% ± 11%.
Early and late allograft-related complications.
There were eight early and late complications specifically
associated with the use of cryopreserved arterial allografts:
Fig 3. Adequate ligature of allograft side branches with through-
and-through polypropylene suture at a descending thoracic aortic
allograft. Isolated ligature of side branches and metallic clips
should be avoided.
Fig 4. Autopsy finding of an allograft-enteric fistula 18 months
after implantation of an aortoiliac bifurcation allograft for pros-
thetic graft infection (original magnification, ×12; van-Gieson-
Elastin).
intraoperative rupture of a friable allograft; early postoper-
ative allograft-rupture caused by inadequate intra-abdom-
inal wound drainage; allograft-enteric fistulas originating
from ruptured side branches of allografts 8, 18, and 48
months after allograft implantation; anastomotic stricture
after partial replacement of an infected thoracic prosthetic
graft13; and late failure of an infrarenal allograft anasto-
mosis caused by continued mechanical stress (in this case,
an aortobi-iliac bifurcation allograft from a tall male donor
had been used to treat an infected aortobifemoral pros-
thesis in a small female patient; the critical length of the
allograft caused inappropriate mechanical stress at the
infrarenal anastomosis, and distraction of the proximal
infrarenal anastomosis associated with persistence of
Candida albicans infection was revealed by means of an
autopsy, but it did not become clinically apparent because
the patient died of an allograft enteric fistula).
There were no other late allograft-related complica-
tions in this study, and allograft enlargement or aneurysm
formation was not observed as long as 8.6 years after allo-
graft implantation. In addition, there was no difference
between patients with complete allograft-replacement and
patients with partial allograft-replacement for infected
prosthetic grafts.
Technical improvements with the use of cryopre-
served allografts. Technical steps have been changed and
specific surgical principles have evolved during this period
of observation (Table III), including: (1) proper timing of
allograft thawing; (2) appropriate length and tension-free
anastomosis ; (3) proper ligature of allograft side branches
by using a through-and-through polypropylene suture
holding of the allograft wall (Fig 3); (4) enlargement of the
anastomotic heel in allograft-to-prosthetic graft anastomo-
sis after partial allograft replacement; (5) avoidance of any
exudate collections around allografts by means of aggressive
wound drainage; (6) circumferential anastomotic reinforce-
ment with allograft strips; (7) entamycin-impregnated fibrin
glue covering all allograft anastomosis; and (8) prolonga-
tion of antifungal treatment to 3 months postoperatively.
Seven of the eight technical problems (87%) previ-
ously mentioned occurred in the first 10 patients (80%) in
this series. However, there was only one technical failure
in the remaining 39 patients (2.6%; P = .0002). These
technical modifications decreased the 30-day mortality
rate to 2.6% (1/39) and eliminated allograft-related late
death. Thus, we believe, that this statistically significant
improvement clearly goes beyond a regular learning curve
to represent the beneficial effect of the surgical technical
improvements described.
DISCUSSION
The use of cryopreserved arterial allografts has evolved
as a distinct technique of treating mycotic aneurysm and
prosthetic graft infection of the thoracic and abdominal
aorta. It is a safe, single-step in situ procedure that limits
extensive perivascular debridment and preserves healthy
autologous tissue. Even difficult to treat vascular infec-
tions, caused by multi-resistant bacteria, are reliably erad-
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icated with cryopreserved allografts. Although this patient
population may be well heterogeneous, it supports the
versatility of arterial allografts that can be used for com-
plex vascular surgical reconstruction of the entire aorta,
including pelvic and groin vessels. Early and late mortality,
morbidity, and reoperation rates compare favorably with
current results achieved in the treatment of major vascular
infections.1,14,15
However, the use of cryopreserved arterial allografts in
infected fields was associated with a considerable learning
curve. Intraoperative and postoperative complications
focused on particular technical problems, and attention to
these difficulties subsequently decreased the incidence of
perioperative and late postoperative adverse events.
A change in the technique to ligate allografts side
branches, done on the bench, probably helped to reduce
the incidence of late allograft-enteric fistulas in patients
receiving infrarenal bifurcation allografts. Single through-
and-through polypropylene suture holding of the allograft
wall was used after a second fistula from an allograft side
branch to the small intestine was proven at autopsy (Fig 4).
Since then, simple ties or metallic clips around allograft side
branches are avoided, and a considerable amount of time is
taken to prepare the arterial allograft, particularly when
using a descending aortic allograft with several pairs of
intercostal arteries. The time-consuming preparation of
freshly thawing allografts before insertion requires adequate
sequencing of intraoperative steps, first to reduce the warm-
ischemia time, rendering allografts friable, and second to
avoid extended aortic cross-clamp times caused by surgical
preparation that has already gone too far.
The appropriate length of aortic allografts is essential.
The ability of cryopreserved allografts to tolerate tensile
strength in vivo has been found to be far below what is
experienced for prosthetic vascular devices, although cryo-
preserved allografts are reported to have a superior
mechanical strength compared with freshly implanted allo-
grafts.16,17 In this series of patients, inadequate tensile
strength has led to intraoperative rupture of an allograft,
requiring an additional allograft to relieve its mechanical
stress. In addition, the healing of a critical allograft anas-
tomosis sutured to the native, yet inflamed aorta may be
compromised by slight anastomotic tension leading to late
anastomotic failure, as observed in a small female patient
who received a large aortoiliac bifurcation prosthesis that
had been used as an aortobifemoral graft.
Table III. Technical modifications evolved with the use
of cryopreserved arterial allografts
Appropriate length of allograft
Absolute tension-free anastomosis
Through-and-through ligature of side branches holding of the 
allograft wall
Anastomotic heel enlargement
Aggressive wound drainage
Anastomotic reinforcement with allograft strips
Gentamycin-impregnated fibrin glue
Avoidance of exudate collections around allografts is
another important point, particularly in patients with
prosthetic aortoenteric fistulas and severely infected peri-
toneal cavities. In our experience, the severity of intraperi-
toneal infection may be quite different in patients with
aortoenteric fistulas; an anastomotic aneurysm below the
origin of the renal arteries that ruptures into the retroperi-
toneal duodenum produces a merely local infection with a
rather clean peritoneal cavity. In these patients, partial
graft replacement of the prosthetic segment involved into
the aortoenteric fistula may be possible, and peritoneal
drainage is easily performed.18 However, aortoenteric fis-
tulas from vascular infection, involving the entire pros-
thetic graft, are more frequently associated with severe
infection of the peritoneal cavity. Peritoneal drainage is
important in these patients, because contaminated wound
secretion may damage the allograft. This is particularly
dangerous when an aortoiliac or aortofemoral bifurcation
allograft has to be composed from three or four different
allograft segments to achieve sufficient length. Although
rarely possible, a complete bifurcation allograft of suffi-
cient length should be chosen in patients with severe
infection of the peritoneal cavity to eliminate the number
of allograft-to-allograft anastomoses. Alternatively, a
descending aortic allograft may be connected to a short
aortic bifurcation allograft, at least reducing the number
of allograft anastomoses. Circumferential anastomotic
reinforcement with allograft strips and covering of all anas-
tomoses with gentamycin-impregnated fibrin glue was
introduced primarily for these particular patients, but was
soon used routinely because antibiotic concentrations in
gentamycin-impregnated fibrin glue have been found to
eradicate even methicillin-resistant Staphylococci. In addi-
tion, antifungal treatment has been extended to 6 months
postoperatively because of one patient with a late persis-
tence of C albicans infection at the proximal anastomosis
of an infrarenal allograft. 
Although it is impossible to differentiate the effect of
any single technical change introduced during this period of
observation, the low early and late infection-related or allo-
graft-related mortality rate compares favorably with the
results reported for the surgical treatment of major aortic
infection. The late mortality rate, unrelated either to the pri-
mary vascular infection or to the use of an allograft, is cer-
tainly troublesome and limits the validity of our late results
as presented. However, it appropriately reflects the many
major comorbidities in this very sick patient population.
Despite these advances, there is an ongoing learning
curve in the treatment of aortic infection, because the best
treatment for aortic fistulas is not established, the optimal
duration of postoperative antibiotic treatment is un-
known, and evidence for less-invasive partial graft replace-
ment is scarce. In addition, an important question is not
yet answered: Why should cryopreserved allografts be
more resistant to infection? Although in vitro studies indi-
cate that cryopreserved allografts produce greater bacter-
ial resistance than knitted Dacron grafts or freshly
implanted allografts, basic mechanisms are largely un-
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known.19,20 The improved bacterial resistance could be
explained by the viability of cryopreserved allografts that
are preserved early after implantation, which allows
improved diffusion of antibiotics into the allograft wall
and the periallograft space. In addition, the allurement of
immunocompetent cells by the allograft may support
eradication of infection. Massive leukocyte invasion
around a cryopreserved allograft was observed by means
of computed tomography-guided puncture of a retroperi-
toneal periallograft space in one of our patients who had
negative results of microbiological testing, including poly-
merase-chain-reaction, which supports this hypothesis.
Another important point addresses the expected long-
term results of cryopreserved vascular allografts. Morpho-
logical and immunohistochemical studies of our explanted
cryopreserved allografts demonstrated a preserved struc-
ture of the matrix constituents, especially the collagenous
network and the glycosaminglycane content, associated
with weak humoral allograft rejection.21 Thus, in contrast
to refrigerated or freshly implanted allografts, cryopre-
served arterial allografts may be immunologically inert,16
and this is supported by the relatively high incidence
(24%) of late refrigerated allograft-related complications
reported by Kieffer, which has not been observed with the
use of cryopreserved allografts.7
Because arterial allografts will degenerate, they may
easily undergo either interventional treatment or replace-
ment with a prosthetic graft once the vascular infection has
been cleared. However, the life expectancy of a cryopre-
served allograft may be longer than that of many patients,
considering the age and comorbidities at the time of
surgery, which reduces the incidence of infection-related
and allograft-related late reoperations. This is similar to
what has been observed after implantation of cryopre-
served heart valve allografts aortic bioprosthesis.
There were several limitations to this study. The num-
ber of patients was limited, and late follow-up data, com-
pared with those presented by Szilagyi,3 are still scarce in
predicting the late behavior of cryopreserved arterial allo-
grafts. Nevertheless, 30-day mortality, actuarial survival,
and actuarial freedom from reoperation rates compare
favorably with results reported in the literature. The dura-
tion of postoperative antibiotic treatment, aimed to be as
short as necessary, was quite variable and has not yet been
fully defined. A larger number of patients is needed to
establish the most cost-effective protocol with the shortest
possible duration of perioperative antibiotic treatment,
especially in patients with, for example, a fungal infection
or an infection caused by difficult to treat organisms. The
indications for using cryopreserved arterial allografts are
not unanimously accepted, especially in patients with an
aortoenteric fistula, in whom allografts have been reported
to fail.22 However, there was no difference in this study
between patients who had a primary or a secondary
abdominal aortic infection with aortoenteric fistulas and
patients without aortoenteric fistula.
In conclusion, in situ repair with cryopreserved arter-
ial allografts has evolved into our technique of choice for
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the treatment of major infection of the thoracic and
abdominal aorta. Because of the implementation of dis-
tinct technical steps, results with allografts improved sig-
nificantly during this study, going beyond a regular
learning curve. 
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